Role Played by Signalling Pathways in Overcoming BRAF Inhibitor Resistance in Melanoma

Role Played by Signalling Pathways in Overcoming BRAF Inhibitor Resistance in Melanoma

The discovery of the BRAFV600E mutation led to the development of vemurafenib (PLX4032), a selective BRAF inhibitor specific to the kinase, for the treatment of metastatic melanomas. However, initial success of the drug was dampened by the development of acquired resistance. Melanoma was shown to re...

Full description

Bibliographic Details
Main Authors: Xian Yang Chan, Alamdeep Singh, Narin Osman, Terrence J. Piva
Format: Article
Language:English
Published: MDPI AG 2017-07-01
Series:International Journal of Molecular Sciences
Subjects:
melanoma
cell signalling
BRAF
MAPK
RTK
PI3K-AKT-mTOR
Online Access:https://www.mdpi.com/1422-0067/18/7/1527

Similar Items

Similar Items